Medication info
BeaRatan Plus Pro Tablet

BeaRatan Plus Pro Tablet

Prescription medicationTablet
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
White to grayish-white oval film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201603092 · Approved 2016.05.31 · Insurance code 694001140

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Substitution therapy: This medicine may replace concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose when creatinine clearance is 30 mL/min or more. Use of loop diuretics rather than thiazide-type drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment cannot be provided by this medicine.
Children's dosage
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used to effectively manage blood pressure in patients with hypertension where blood pressure is not sufficiently controlled by monotherapy alone.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Substitution therapy: This medicine may replace concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose when creatinine clearance is 30 mL/min or more. Use of loop diuretics rather than thiazide-type drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Administration to these patients is not recommended because the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment cannot be provided by this medicine.

Children's dosage

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, and should not be taken by women who are pregnant or may become pregnant. Patients who are allergic to any ingredient in this medication or who have certain kidney and liver diseases or electrolyte imbalances should not use it. Patients with excessively low blood pressure or severe renal impairment, and those with certain genetic diseases should also not take this medication. When taking this medication, careful observation for adverse effects such as hypotension, electrolyte imbalance, renal function abnormalities, hepatic function abnormalities, hyperuricemia, blood glucose changes, and skin rash or allergic reactions should be conducted. The hydrochlorothiazide component can alter electrolyte levels in the body, thus regular blood tests and electrolyte checks are necessary. This medication may interact with other antihypertensives, diuretics, potassium supplements, non-steroidal anti-inflammatory drugs, and lithium preparations, so if you are taking other medications, it is essential to consult with a healthcare provider. During the course of taking this medication, sudden dizziness or drowsiness may occur, necessitating caution when driving or operating machinery. The safety of this medication in children and adolescents has not been established, and elderly patients may experience more frequent adverse reactions, making caution necessary. Pregnant or nursing mothers should avoid taking this medication, and particularly nursing mothers should either discontinue breastfeeding or consult with a physician. Signs of overdose may include hypotension and changes in heart rate; immediate medical attention is required. This medication should be stored out of reach of children and kept in its original container, and the container or storage methods should not be altered.

Side effects

  • Abdominal pain
  • swelling
  • palpitations
  • lower back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
Show 124 more
  • skin peeling
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • indigestion
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle spasms
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory disturbance
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurodermatitis
  • panic disorder
  • sensory abnormality
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturnal enuresis
  • frequency of urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • agitation
  • renal failure
  • renal impairment
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it is important to store the medication at room temperature, that is, between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white oval film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.